Genmab A/S
Forward trial catalysts linked to GMAB
CSA tracks 3 forward catalysts for Genmab A/S across 3 assets, spanning Phase 3. The nearest is a readout expected Jun 2027 (month precision). Confidence across its tracked catalysts breaks down as 3 medium. Tracked indications include PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC, Diffuse Large B-cell Lymphoma, Follicular Lymphoma (FL), and 5 more.
GMAB in the full snapshot
The free sample on this page is a slice. In the current full CSA snapshot, Genmab A/S has:
Forward catalysts by year
Every catalyst in the snapshot comes with its date, date confidence and source link.
13 trials behind these assets
| Asset | Trial | Phase | Status | Primary completion | Role | Lead sponsor | Condition(s) |
|---|---|---|---|---|---|---|---|
| epcoritamab | NCT04628494 | Phase 3 | Active, not recruiting | 2025-10-13 | Experimental | Genmab | Diffuse Large B-cell Lymphoma |
| epcoritamab | NCT07226752 | Phase 3 | Active, not recruiting | 2025-10-13 | Experimental | Genmab | Diffuse Large B-Cell Lymphoma |
| rinatabart sesutecan | NCT06619236 | Phase 3 | Active, not recruiting | 2026-08-18 | Experimental | Genmab | Platinum-resistant Ovarian Cancer |
| epcoritamab | NCT05578976 catalyst | Phase 3 | Active, not recruiting | 2027-06 | Experimental | Genmab | Diffuse Large B-Cell Lymphoma |
| acasunlimab | NCT06635824 catalyst | Phase 3 | Active, not recruiting | 2027-07-30 | Experimental | Genmab | PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC |
| rinatabart sesutecan | NCT07604766 catalyst | Phase 3 | Recruiting | 2027-09 | Experimental | Genmab | Platinum-resistant Ovarian Cancer |
| epcoritamab | NCT06508658 | Phase 3 | Active, not recruiting | 2028-03 | Experimental | Genmab | Diffuse Large B-Cell Lymphoma |
| rinatabart sesutecan | NCT07225270 | Phase 3 | Recruiting | 2028-10 | Experimental | Genmab | Ovarian Cancer; Platinum-sensitive Ovarian Cancer; PSOC |
| rinatabart sesutecan | NCT07166094 | Phase 3 | Recruiting | 2029-08 | Experimental | Genmab | Endometrial Cancer; Recurrent or Progressive Endometrial Cancer |
| epcoritamab | NCT05409066 | Phase 3 | Active, not recruiting | 2029-12 | Experimental | Genmab | Follicular Lymphoma (FL) |
| rinatabart sesutecan | NCT07564141 | Phase 3 | Recruiting | 2029-12 | Experimental | Genmab | Platinum-Sensitive Ovarian Cancer; Ovarian Cancer |
| rinatabart sesutecan | NCT07859215 | Phase 3 | Not yet recruiting | 2030-03 | Experimental | Genmab | Ovarian Cancer |
| epcoritamab | NCT06191744 | Phase 3 | Active, not recruiting | 2037-11 | Experimental | Genmab | Follicular Lymphoma (FL) |
Every trial the CSA sample links to GMAB's tracked assets.
Conditions studied
Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.
This sponsor's catalysts are a slice of the free CSA sample. The full snapshot covers active, industry-sponsored Phase 3 trials in cardiometabolic, oncology and immunology. Every forward catalyst carries its date, confidence grade and source link, and is linked to its sponsor's ticker when the sponsor is a listed company.
Get the full dataset — $499 →